Skip to main content

Table 5 Multivariate analysis of factors associated with DFS and OS in post- menopausal patients

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Characteristics DFS OS
HR (95% CI) P value HR (95% CI) P value
Neo-adjuvant therapy (Yes vs. No) 2.24 (1.51–3.30) <  0.001 2.18 (1.30–3.66) 0.003
Breast surgery (BCS vs. Mastectomy) / / 0.92 (0.59–1.44) 0.722
Tumor size (>  2.0 cm vs. ≤ 2.0 cm) 1.46 (1.13–1.89) <  0.001 1.53 (1.06–2.20) 0.024
ALN status (Positive vs. Negative) 1.74 (1.34–2.26) <  0.001 2.23 (1.55–3.19) <  0.001
Histological grade   <  0.001   0.004
III vs. I/II 1.54 (1.13–2.09)   1.53 (1.00–2.36)  
NA vs. I/II 2.05 (1.48–2.85)   2.08 (1.31–3.29)  
ER   0.043   < 0.001
10–49% vs. 1–9% 1.56 (0.76–3.21)   1.01 (0.47–2.18)  
≥ 50% vs. 1–9% 1.02 (0.51–2.02)   0.45 (0.22–0.93)  
PR (≥ 20% vs. <  20%) 0.84 (0.64–1.09) 0.194 0.76 (0.52–1.13) 0.177
Ki-67 (≥ 14% vs. <  14%) 1.50 (1.14–1.99) 0.004 1.39 (0.94–2.07) 0.098
Radiotherapy (Yes vs. No) 0.91 (0.66–1.25) 0.549 1.13 (0.71–1.79) 0.605
Chemotherapy (Yes vs. No) 1.12 (0.83–1.52) 0.466 / /
Endocrine therapy (Yes vs. No) 0.56 (0.37–0.86) 0.007 0.53 (0.31–0.91) 0.021
Group (HER2-pos-T vs. HER2-neg) 0.52 (0.32–0.85) 0.005 0.37 (0.17–0.77) 0.008
  1. HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; ALN, axillary lymph node; ER, estrogen receptor; PR, progesterone receptor; y/o, years old